- Celanese Corp (NYSE:CE) has received a grant from the Bill & Melinda Gates Foundation to produce and characterize a working prototype for a refillable contraceptive implant.
- CE expects the project to produce a functional prototype that meets all established project parameters within an 18-month timeframe.
- Through this grant, Celanese will provide critical research and development activities to facilitate and accelerate access to long-acting contraceptive options.
- “The project concept is based on our VitalDose® drug delivery platform, a controlled release technology with decades of commercial use in the US and Europe,” commented Laura Brand, VP of the Celanese medical and pharmaceutical business.
- Price Action: CE shares are trading lower by 0.04% at $115.95 on the last check Wednesday.
MDxHealth Reports Preliminary Q4 Revenue $19.4M Vs $18.35M Est.; Sees FY23 Revenue $70.2M Vs $69.15M Est.; Sees FY24 Revenue $79M-$81M Vs $78.57M Est.
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenuesand Issues 2024 Revenue GuidanceIRVINE, CA, and HERSTAL, BELGIUM – January 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a commercial-stage
